コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 e epoxide ring-opening reaction catalyzed by epoxide hydrolase.
2 ctivity of the P450s and regioselectivity of epoxide hydrolase.
3 es, a reaction specificity characteristic of epoxide hydrolase.
4 identified inhibitors of the enzyme soluble epoxide hydrolase.
5 homogenates and is primarily metabolized by epoxide hydrolase.
6 yethanes are not accepted by known bacterial epoxide hydrolases.
7 and Tyr(381) is conserved among the soluble epoxide hydrolases.
8 kotoxin is only cytotoxic in the presence of epoxide hydrolases.
9 to dihydroxyeicosatrienoic acids (DHETs) by epoxide hydrolases.
10 for epoxide selection by ionophore polyether epoxide hydrolases.
11 enes, cytochrome P-450 1A1 (CYP1A1) MspI and epoxide hydrolase 1 (EPHX1) Tyr113His, affect the associ
14 as a set of rare and common variants in the Epoxide Hydrolase 2 (EPHX2) gene, in an initial sequenci
16 olysis of EETs by soluble epoxide hydrolase/ epoxide hydrolase 2 (sEH/EPHX2) to less active diols att
17 ne products (fatty acid desaturases 1 and 2, epoxide hydrolase 2, lysophosphatidylcholine acetyl-tran
19 e hydrolase activity of M. thermoresistibile epoxide hydrolase A (Mth-EphA) and report its crystal st
20 basal and inducible expression of microsomal epoxide hydrolase, a key enzyme in the detoxification of
21 e with the same stereochemistry as that from epoxide hydrolase action on the natural JH antipode.
22 xtensive hydrophobic contacts in the soluble epoxide hydrolase active site, and each urea carbonyl ox
24 ial cells and in this state does not exhibit epoxide hydrolase activity (i.e. conversion of LTA4 to L
25 oduct (FosX(Ml)) from M. loti has a very low epoxide hydrolase activity and even lower glutathione tr
33 peptidases, aldosterone synthase and soluble epoxide hydrolase, agonists of natriuretic peptide A and
35 tion; Tyr(465) is highly conserved among all epoxide hydrolases, and Tyr(381) is conserved among the
36 oli expressing recombinant Aspergillus niger epoxide hydrolase as the model enzyme for various enanti
37 se (GCS), UDP-glucuronosyltransferases (UGT),epoxide hydrolase, as well as a number of new genes.
39 r the first time we demonstrate that soluble epoxide hydrolase can bioactivate epoxides to diols that
42 nd immunological evidence that the bacterial epoxide hydrolase Cif disrupts resolution pathways durin
43 whether zinc-mediated inhibition of soluble epoxide hydrolase contributes to the development of PH a
45 osynthetic pathway resembles other polyether epoxide hydrolases/cyclases of the MonB family, but SalB
46 Here, we show that a secreted P. aeruginosa epoxide hydrolase, cystic fibrosis transmembrane conduct
47 squalene epoxidases, triterpenoid synthases, epoxide hydrolases, cytochrome P450s, and UDP-glucosyltr
48 450s (P450s) and regioselective hydration by epoxide hydrolase determine the carcinogenic potency of
49 exene oxide, a known inhibitor of microsomal epoxide hydrolase, did not affect the production of meta
50 yme with two catalytic domains: a C-terminal epoxide hydrolase domain and an N-terminal phosphatase d
52 ucture of recombinant murine liver cytosolic epoxide hydrolase (EC 3.3.2.3) has been determined at 2.
54 uctural underpinnings of the enzyme's unique epoxide hydrolase (EH) activity, involving Zn(2+), Y383,
56 of neonatal faeces indicated that bacterial epoxide hydrolase (EH) genes are more abundant in the gu
57 s of prometryn are associated with increased epoxide hydrolase (EH) products, increased sEH and mEH e
58 at Cif is capable of degrading the synthetic epoxide hydrolase (EH) substrate S-NEPC [(2S,3S)-trans-3
59 l sequence analysis suggested that Cif is an epoxide hydrolase (EH), but its sequence violates two st
62 s M. tuberculosis has six putative genes for epoxide hydrolases (EH) of the alpha/beta-hydrolase fami
64 s the founding member of a distinct class of epoxide hydrolases (EHs) that triggers the catalysis-dep
66 of LA (EpOMEs) are hydrolyzed by the soluble epoxide hydrolase enzyme (sEH) to dihydroxyoctadecenoic
67 he hypotheses that inhibition of the soluble epoxide hydrolase enzyme can result in an increase in th
69 urea-like compounds that inhibit the soluble epoxide hydrolase enzyme in mice and humans is examined.
70 pproach to increase EET levels is to inhibit epoxide hydrolase enzymes that are responsible for conve
71 TNF receptor 3 '-flanking region gene, human epoxide hydrolase (EPHX), human growth/differentiation f
74 on approach identified four genes-microsomal epoxide hydrolase (EPHX1), latent transforming growth fa
75 depended upon co-administration of a soluble epoxide hydrolase (EPHX2) inhibitor in males, and/or wer
76 termine whether genetic variation in soluble epoxide hydrolase (EPHX2) was associated with the risk o
79 s with loss-of-function mutations in soluble epoxide hydrolase exhibited a higher risk of developing
80 summary, in mice, TSO increases Cyp2b10 and epoxide hydrolase expression in mice via CAR, and potent
81 atient lung samples showed decreased soluble epoxide hydrolase expression, echoing our findings with
82 le comparisons, only one polymorphism in the epoxide hydrolase family 2 locus remained significantly
84 CIMB 13064, and haloalcohol dehalogenase and epoxide hydrolase from Agrobacterium radiobacter AD1.
85 rt the in vitro characterization of SgcF, an epoxide hydrolase from the C-1027 biosynthetic gene clus
86 association of polymorphisms in the soluble epoxide hydrolase gene (EPHX2) with incident ischemic st
87 ong women AA for rs2234922 in the microsomal epoxide hydrolase gene, EPHX1 (OR = 1.77, 95% CI: 1.06,
91 erritin (heavy and light chains), microsomal epoxide hydrolase, glutathione S-transferase, and gamma-
93 d evolution to a variety of enzymes, such as epoxide hydrolase, glyphosate N-acetyltransferase, xylan
94 ic system that was catalysed by limonene-1,2-epoxide hydrolase, had an intracellular nature and was c
95 rea inhibitors complexed with murine soluble epoxide hydrolase have been determined by x-ray crystall
96 ally active, as assessed by the induction of epoxide hydrolase, heme oxygenase-1, and glutamate cyste
97 2b10, NAD(P)H:quinone oxidoreductase (Nqo1), epoxide hydrolase, heme oxygenase-1, UDP-glucuronosyl-tr
100 (SIM) to study the kinetics of human soluble epoxide hydrolase (hsEH), an enzyme involved in cardiova
101 erminal methionine PTS1 (SKM), human soluble epoxide hydrolase (hsEH), shows both peroxisomal and cyt
102 first direct evidence for a role for soluble epoxide hydrolase in blood pressure regulation and ident
103 cificity that implicates participation of an epoxide hydrolase in converting epoxyalcohol to triol.
106 protected from acute hypoxia-induced soluble epoxide hydrolase inhibition, epoxyeicosatrienoic acid a
107 e to epoxyeicosatrienoic acid, zinc, soluble epoxide hydrolase inhibition, or hypoxia treatment.
108 tivity assays measured zinc-mediated soluble epoxide hydrolase inhibition, with mutagenesis and induc
112 ) are coadministered with a low-dose soluble epoxide hydrolase inhibitor, EDPs are stabilized in circ
113 beneficial effects of several potent soluble epoxide hydrolase inhibitors (sEHIs) in different models
115 quinone reductase, glucuronosyltransferases, epoxide hydrolase) is a major strategy for reducing the
118 olymorphisms in the gene encoding microsomal epoxide hydrolase (mEH) among 464 cases diagnosed with f
123 es have suggested that the enzyme microsomal epoxide hydrolase (mEH) is able to mediate sodium-depend
127 e enzymatic activities of sEH and microsomal epoxide hydrolase (mEH) were elevated by ibuprofen in bo
128 Two of these genes, SM20 and microsomal epoxide hydrolase (mEH), are previously described genes.
129 immunosuppression is CYP1B1- and microsomal epoxide hydrolase (mEH)-dependent, demonstrating that th
132 her polymorphisms in the gene for microsomal epoxide hydrolase (mEPHX), an enzyme involved in this pr
133 ere observed between cytochrome p450/soluble epoxide hydrolase metabolites, bile acids, and proteins
136 ion enzymes [e.g., glutathione transferases, epoxide hydrolase, NAD(P)H: quinone reductase, and glucu
139 Systolic blood pressure of male soluble epoxide hydrolase-null mice was lower compared with wild
141 rienoic acids was markedly lower for soluble epoxide hydrolase-null versus wild-type mice of both sex
142 nd can be catalyzed in a non-redox manner by epoxide hydrolases or reductively by oxidoreductases.
145 e, reconstituted CYP1A1-Ile462 together with epoxide hydrolase produced 7,8- and 9,10-dihydrodiols at
146 AAG with cloned CYP3A4 and cloned microsomal epoxide hydrolase produced metabolites 2 and 4, with gre
147 Ephx2 gene disruption eliminated soluble epoxide hydrolase protein expression and activity in liv
148 e report findings that inhibition of soluble epoxide hydrolase reduces inflammation, oxidative stress
150 Notably, AmbK is identified as the elusive epoxide hydrolase responsible for the formation of the t
153 ds as dual inhibitors of the enzymes soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE),
156 In addition, both human recombinant soluble epoxide hydrolase (sEH) and the glutathione S-transferas
157 n of dual-target ligands that target soluble epoxide hydrolase (sEH) and the peroxisome proliferator-
158 hesized by CYP450 and catabolized by soluble epoxide hydrolase (sEH) are involved in the maintenance
163 l trials combined with inhibition of soluble epoxide hydrolase (sEH) as anti-inflammatory strategy pr
164 sition-state mimic that inhibits the soluble epoxide hydrolase (sEH) at picomolar concentrations.
168 enetic ablation or inhibition of the soluble epoxide hydrolase (sEH) enzyme led to increased levels o
169 HA metabolism by cytochrome P450 and soluble epoxide hydrolase (sEH) enzymes affects retinal angiogen
170 The X-ray crystal structure of human soluble epoxide hydrolase (sEH) has been determined at 2.6 A res
173 hydroxyeicosatrienoic acid (DHET) by soluble epoxide hydrolase (sEH) in mammalian tissues, and inhibi
175 tion of endogenous epoxide levels by soluble epoxide hydrolase (sEH) in the endothelium represents an
176 sistent with increased expression of soluble epoxide hydrolase (sEH) in the SHR renal microsomes and
178 revious study showed that inhibiting soluble epoxide hydrolase (sEH) increased EET concentration and
183 rational development of a library of soluble epoxide hydrolase (sEH) inhibitors for the treatment of
184 tandem mass spectrometric method for soluble epoxide hydrolase (sEH) inhibitors in rat hepatic micros
187 The emerging pharmacological target soluble epoxide hydrolase (sEH) is a bifunctional enzyme exhibit
196 The pharmacological inhibition of soluble epoxide hydrolase (sEH) is efficient for the treatment o
202 cids (EETs) from the cytochrome P450/soluble epoxide hydrolase (sEH) pathway are important eicosanoid
203 of the cyclooxygenase-2 (COX-2) and soluble epoxide hydrolase (sEH) pathways prevented the debris-in
204 erging of 5-lipoxygenase (5-LOX) and soluble epoxide hydrolase (sEH) pharmacophores led to the discov
209 rvations that urea inhibitors of the soluble epoxide hydrolase (sEH) reduce blood pressure in spontan
210 n vivo pharmacological inhibition of soluble epoxide hydrolase (sEH) reduces inflammatory diseases, i
213 r studies identified oxamide 2b as a soluble epoxide hydrolase (sEH) stable replacement but unsuitabl
214 ompounds, which are converted by the soluble epoxide hydrolase (sEH) to dihydroxylethersatrienoic aci
215 xy-fatty acids through inhibition of soluble epoxide hydrolase (sEH) was shown to reduce diabetic neu
216 unbinding paths for an inhibitor of soluble epoxide hydrolase (sEH) with a residence time of 11 min.
218 icacy of pharmacologic inhibition of soluble epoxide hydrolase (sEH), an enzyme involved in lipid met
221 cytochrome P450 epoxygenases and the soluble epoxide hydrolase (sEH), and targeting the latter is an
222 ne, and because its protein product, soluble epoxide hydrolase (sEH), converts bioactive epoxides of
223 -regulates cyclooxygenase-2 (COX-2), soluble epoxide hydrolase (sEH), ER stress-response genes includ
225 ered in the N-terminal domain of the soluble epoxide hydrolase (sEH), opening a new branch of fatty a
228 ET levels are typically regulated by soluble epoxide hydrolase (sEH), the major enzyme degrading EETs
229 sible for EETs synthesis, as well as soluble epoxide hydrolase (sEH), which metabolizes EETS to DHETs
230 examined the effect of FABPs on the soluble epoxide hydrolase (sEH)-mediated conversion of EETs to d
231 tyl-ureido-dodecanoic acid (AUDA), a soluble epoxide hydrolase (sEH)-specific inhibitor, EETs increas
242 pyridine and an urea moiety as novel soluble epoxide hydrolase (sEH)/5-lipoxygenase (5-LO) dual inhib
243 of EETs is limited primarily by the soluble epoxide hydrolase (sEH, EPHX2), which metabolizes EETs t
244 iated EET biosynthesis and decreased soluble epoxide hydrolase (sEH, Ephx2)-mediated EET hydrolysis o
248 ipid-derived chemotactic activity is soluble epoxide hydrolase sensitive, consistent with hepoxilin A
250 ylstyrene oxide in the active site of murine epoxide hydrolase show two possible binding conformation
251 eficial biofilm was engineered to produce an epoxide hydrolase so that it efficiently removes the env
252 opropylene 1,2-oxide (TCPO), an inhibitor of epoxide hydrolase, suggesting that P450 enzymes exhibite
254 in Pseudomonas aeruginosa, Cif is a secreted epoxide hydrolase that is transcriptionally regulated by
258 pathway whereby 11,12-EET is converted by an epoxide hydrolase to 11,12-DHET, which then undergoes tw
260 s that can be further metabolized by soluble epoxide hydrolase to the corresponding dihydroxyeicosatr
264 ressed human and mouse P450s 1A1 and 1A2 and epoxide hydrolase were used to characterize the stereose
265 sis-related protein 1.2, heme oxygenase, and epoxide hydrolase) were demonstrated to be regulated by
266 mic substrate could be exploited to engineer epoxide hydrolases with improved regio- and/or enantiosp
267 s (YknXYZ), non-haem bromoperoxidase (YdjP), epoxide hydrolase (YfhM) and three small peptides with s